Document is current

Article History

Received: 22 May 2025

Accepted: 12 September 2025

First Online: 24 October 2025

Declarations

:

: Our institution does not require ethical approval for reporting individual cases.

: Written information consent was obtained from the patient to participate in this case report.

: Written information consent was obtained from the patient for their anonymized information to be published in this article.

: RH serves as PI with trials for Otsuka, Alexion, Remegen, Roche, Apellis, Calliditas, and Novartis pharmaceuticals. He also serves as a consultant and advisor for Novartis, Alexion, and Calliditas. He serves on the speaker’s bureau for Otsuka, Alexion, Calliditas, Aurinia, GSK, and Calliditas. SC served as advisory board member for Hansa Biopharma, CareDx, Spectrum/Achrotech, Kiadis Pharma, Allogene Celularity, MolMed, Pharmacyclics and received research funds from Kiadis and Miltenyi Biotech. M. Tran received an honoraria from Sanofi. ARK owns stock and ownership interests in ECOM Medical and has received honoraria from companies such as Exelixis, Bayer, Eisai, Aveo, and AstraZeneca. Additionally, he has served on the Speakers’ Bureau for Janssen, Pfizer, and Sanofi. ARK has also received travel, accommodations, and expenses from Janssen, Eisai, Bayer, and Exelixis. Furthermore, he has received research funding from numerous companies including Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol-Myers Squibb, and others.